-
Goldman Sachs Considers Implications For Regeneron, Amgen, Sanofi Following PCSK9 Ruling
Thursday, March 17, 2016 - 7:45am | 427Read More...The U.S. District Court jury ruled in favor of Amgen, Inc. (NASDAQ: AMGN) in the PCSK9 patent litigation. Both Amgen’s Repatha and Praluent by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY) are antibodies to PCSK9 that had been approved in the US and EU in 2015...
-
Clovis Oncology, FibroGen Are Key Biotech Names For Goldman Sachs
Monday, July 20, 2015 - 7:56am | 425Read More...In a report published Sunday, Goldman Sachs analyst Terence Flynn discussed the biotech space, noting the sector's most commonly referenced index, the NASDAQ Biotechnology (INDEX: NBI) gained 28 percent year-to-date, drastically outperforming the S&P 500's 2 percent return over the...
-
Goldman Sachs Comments on How Strong Sales of Kyprolis, Epogen, and Prolia Might Affect Amgen
Friday, November 29, 2013 - 12:00pm | 127Read More...In a report published Friday, Goldman Sachs analyst Terence Flynn reiterated a Buy rating and $130.00 price target on Amgen (NASDAQ: AMGN). In the report, Goldman Sachs noted, “AMGN IMS monthly drug sales are tracking slight ahead of our estimates. Kyprolis, Epogen and Prolia are particularly...
-
UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals Following Complete Phase 3 Eye Drug Data
Monday, September 30, 2013 - 12:25pm | 96Read More...In a report published Monday, Goldman Sachs analyst Terence Flynn reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $329.00 to $355.00. In the report, Goldman Sachs noted, “REGN reported complete Phase 3 data for key eye drug, Eylea for a new...
-
UPDATE: Goldman Sachs Initiates Agios Pharmaceuticals with Buy on Emerging Leadership Position
Monday, August 19, 2013 - 10:21am | 138Read More...In a report published Monday, Goldman Sachs analyst Terence Flynn initiated coverage on Agios Pharmaceuticals (NASDAQ: AGIO) with a Buy rating and $37.00 price target. In the report, Goldman Sachs noted, “We initiate coverage of AGIO at Buy with a 12-month price target of $37. We see the company...
-
UPDATE: Goldman Sachs Downgrades Cubist Pharmaceuticals Following Removal from Conviction List
Wednesday, July 31, 2013 - 9:37am | 163Read More...In a report published Wednesday, Goldman Sachs analyst Terence Flynn downgraded Cubist Pharmaceuticals (NASDAQ: CBST) from Buy to Neutral, but reiterated the $59.00 price target. In the report, Goldman Sachs noted, “We are downgrading CBST to Neutral from Buy and removing it from the Americas...
-
UPDATE: Goldman Sachs Reiterates Buy Rating, $130 PT on Amgen Ahead of AMG 386 Phase 3 Data
Wednesday, May 22, 2013 - 8:29am | 105Read More...In a report published Wednesday, Goldman Sachs analyst Terence Flynn reiterated a Buy rating and $130.00 price target on Amgen (NASDAQ: AMGN). In the report, Goldman Sachs noted, “We expect AMGN to report the first Ph3 data for pipeline cancer drug Trebananib (AMG 386) in the next few months....
